Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 23Ovarian Neoplasms 20Triple Negative Breast Neoplasms 12Neoplasms 9Neoplasm Metastasis 9Fallopian Tube Neoplasms 9Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Glioblastoma 5Astrocytoma 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Gliosarcoma 4Colonic Neoplasms 4Brain Neoplasms 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Melanoma 3Lymphoma 3Lung Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Thrombocythemia, Essential 2Testicular Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Recurrence × veliparib × Clear all
NCT01199224 2017-11-21

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
27 enrolled

Recurrence

NCT01472783 2016-11-16

Veli-BRCA

Vejle Hospital

Phase 1/2 Completed
49 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

NCT01193140 2012-11-21

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Abbott

Phase 2 Completed
24 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡